<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1">
  <url>
    <loc>https://www.cellima.com/insights</loc>
    <changefreq>daily</changefreq>
    <priority>0.75</priority>
    <lastmod>2025-12-10</lastmod>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/nk1-antagonist-journey</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
    <lastmod>2025-12-10</lastmod>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/b66d6d6e-f6db-4a22-b298-9a51f730d2c7/CELLIMATALKS-VII-WebSite-01.png</image:loc>
      <image:title>Insights - Inside an NK1 Antagonist Journey: A Pharmacologist’s Perspective - Mike Snider is a retired pharmacologist with decades of experience in early-stage drug discovery. He earned his PhD in Pharmacology at Ohio State University and completed a postdoctoral fellowship at the Mayo Clinic, focusing on biogenic receptor systems. At Pfizer, he played a central role in the NK1 receptor antagonist project, contributing to therapies that improve patient outcomes in chemotherapy and post-operative care.</image:title>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/ae1d82d6-ef91-4738-a4c9-88728d8c4904/CELLIMATALKS-VII-WebSite-03.png</image:loc>
      <image:title>Insights - Inside an NK1 Antagonist Journey: A Pharmacologist’s Perspective - Mach es besonders</image:title>
      <image:caption>Was auch immer es ist – die Art und Weise, wie du deine Geschichte online vermittelst, kann einen gewaltigen Unterschied ausmachen.</image:caption>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/0e02f292-6ec0-40d6-b173-5a8427e68b36/CELLIMATALKS-VII-WebSite-08.png</image:loc>
      <image:title>Insights - Inside an NK1 Antagonist Journey: A Pharmacologist’s Perspective - Mach es besonders</image:title>
      <image:caption>Was auch immer es ist – die Art und Weise, wie du deine Geschichte online vermittelst, kann einen gewaltigen Unterschied ausmachen.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/mosaic-microscope</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
    <lastmod>2025-09-08</lastmod>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/1753123455002-TUYXH9IAUFQ1999DY1HI/MOSAIC-Tubus.jpg</image:loc>
      <image:title>Insights - MOSAIC – One Microscope to Rule Them All? - MOSAIC is a modular microscope integrating twelve imaging modes with adaptive optics in a single platform. Led by the Wesley R. Legant and Srigokul Upadhyayula labs, with key contributions from Eric Betzig (Betzig lab), the system rethinks multimodal imaging from the ground up.</image:title>
      <image:caption>This post highlights its architecture, application range, and strategic relevance for high-end imaging environments. DOI: 10.1101/2025.06.02.657494</image:caption>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/37b4181b-07ab-44ab-9f68-ccd5d0ba9f72/Man-Microscope.png</image:loc>
      <image:title>Insights - MOSAIC – One Microscope to Rule Them All? - Mach es besonders</image:title>
      <image:caption>Was auch immer es ist – die Art und Weise, wie du deine Geschichte online vermittelst, kann einen gewaltigen Unterschied ausmachen.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/deep-pheno-alpha-fold</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
    <lastmod>2025-12-09</lastmod>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/1756492530780-0K3H2TUR0GV5TJB9S23N/Werbe-Banner-CTVI-241010-PodCast.jpg</image:loc>
      <image:title>Insights - Deep Phenotyping And AlphaFold</image:title>
    </image:image>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/ion-channels-drug-discovery</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
    <lastmod>2025-12-09</lastmod>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/1756492527720-95XGOGGMA6O2NBGCPTJ1/Werbe-Banner-CTV-240820.webp</image:loc>
      <image:title>Insights - Guardians of Health</image:title>
      <image:caption>Thomas Müller</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/category/Imaging+Strategy</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/category/Research+Reviews</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/category/Insights</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/category/Tech+Landscape</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/category/CELLIMA+TALKS</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/category/From+Bench+to+Blog</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/category/Technology+Reviews</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/AI-driven+Imaging</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/screening</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/pharmaceutical+research</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/NK1+receptor</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/Imaging+Infrastructure</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/Pfizer</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/High-Content+Imaging</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/CELLIMA+TALKS</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/Marc+Bickle</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/Drug+Discovery</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/artificial+intelligence</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/ion+channels</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/MOSAIC</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/early+research</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/personalized+medicine</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/healthcare</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/deep+learning</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/High-Throughput+Screening</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/Thomas+M%C3%BCller</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/drug+discovery</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/AlphaFold</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/high-content+imaging</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/Deep+Phenotyping</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/insights/tag/Adaptive+Optics</loc>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://www.cellima.com/contact-me</loc>
    <changefreq>daily</changefreq>
    <priority>0.75</priority>
    <lastmod>2026-03-05</lastmod>
  </url>
  <url>
    <loc>https://www.cellima.com/home</loc>
    <changefreq>daily</changefreq>
    <priority>1.0</priority>
    <lastmod>2026-03-06</lastmod>
  </url>
  <url>
    <loc>https://www.cellima.com/newsletter</loc>
    <changefreq>daily</changefreq>
    <priority>0.75</priority>
    <lastmod>2025-07-14</lastmod>
  </url>
  <url>
    <loc>https://www.cellima.com/meet-stefan</loc>
    <changefreq>daily</changefreq>
    <priority>0.75</priority>
    <lastmod>2026-03-06</lastmod>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/9c1c978b-9394-4b98-a0b3-f03bb7d201e2/Andrea.jpeg</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/d21c8f44-aa91-4d83-83a0-7af78d5cb961/AMF.jpeg</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/d0bd55f0-42ab-4378-8506-44b45438568f/Mike.jpeg</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/e4104392-4ad9-4cf3-bbc8-adaa0bb8651d/FRicci.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.cellima.com/what-cellima-does</loc>
    <changefreq>daily</changefreq>
    <priority>0.75</priority>
    <lastmod>2026-03-09</lastmod>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/b0e7b8b6-d85b-429c-97b8-847ca8ffba3d/Face_01.png</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/d8200182-2793-4344-bbf2-492fa3499640/8.png</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/27a96e22-50e7-4aed-bd73-3714d8d8db89/Pipette_01.png</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/5e96a7d4-c84d-4c0c-81e4-48ed37c38a1c/7.png</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/8540855c-55d5-4d51-9b11-0d7396affedb/Face_03.png</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/d784ea64-9e09-40b4-848f-e56ebe13f039/1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.cellima.com/discuss</loc>
    <changefreq>daily</changefreq>
    <priority>0.75</priority>
    <lastmod>2026-03-09</lastmod>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/d784ea64-9e09-40b4-848f-e56ebe13f039/1.png</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/d784ea64-9e09-40b4-848f-e56ebe13f039/1.png</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/d784ea64-9e09-40b4-848f-e56ebe13f039/1.png</image:loc>
    </image:image>
    <image:image>
      <image:loc>https://images.squarespace-cdn.com/content/v1/67e3cdd28248591fa0e2b98f/d784ea64-9e09-40b4-848f-e56ebe13f039/1.png</image:loc>
    </image:image>
  </url>
</urlset>

